# Pazopanib as Single Agent in Advanced NETs

> **NCT01280201** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 44 (actual)

## Conditions studied

- Advanced/Metastatic Neuroendocrine Tumors

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01280201
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-26
- **Primary completion:** 2013-04
- **Final completion:** 2015-03-15
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01280201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01280201, "Pazopanib as Single Agent in Advanced NETs". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01280201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*